Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Long-Term Investments data on file, last reported at $22.2 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 67.68% year-over-year to $22.2 million; the trailing twelve-month figure through Mar 2026 stood at $22.2 million (down 67.68% YoY), and the FY2025 full-year result was $22.2 million, down 67.68% from the prior year.
• Long-Term Investments for Q1 2026 stood at $22.2 million, roughly flat from $22.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $68.6 million in Q4 2024 and bottomed at $22.2 million in Q4 2025.
• The 5-year median for Long-Term Investments is $49.4 million (2022), against an average of $50.3 million.
• The widest annual swing landed in 2024, when Long-Term Investments soared 38.88%; it then plunged 67.68% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $49.4 million in 2022, then increased by 0.0% to $49.4 million in 2023, then jumped by 38.88% to $68.6 million in 2024, then slumped by 67.68% to $22.2 million in 2025, then changed by 0.0% to $22.2 million in 2026.
• The last three Long-Term Investments figures came in at $22.2 million (Q1 2026), $22.2 million (Q4 2025), and $51.3 million (Q3 2025), per Business Quant data.

Peer Comparison